Janus

First Trust Dynamic Europe Equity Income Fund Declares its Monthly Common Share Distribution of $0.07 Per Share for April

Retrieved on: 
Monday, March 20, 2023
Banking, Professional Services, Finance, Janus, Vaccine, AIB (NI), Uncertainty, New York Stock Exchange, Plan, European Central Bank, Loss, ERISA, Investment, REIT, Hedge fund, Policy, COVID-19, NAV, Central bank, Infection, Risk, Terrorism, Judgement, Internal Revenue Code, FTP, Real estate investment trust, US, Trustee, Social change, Indian stock exchange, European, FINRA, Economic development, City, Security (finance), Fraud, Janus Henderson, NYSE, FTA, Disease, Life insurance, Financial adviser, Bank, Financial services, EU, Euro, Fund

First Trust Dynamic Europe Equity Income Fund (the "Fund") (NYSE: FDEU) has declared the Fund’s regularly scheduled monthly common share distribution in the amount of $0.07 per share payable on April 17, 2023, to shareholders of record as of April 4, 2023.

Key Points: 
  • First Trust Dynamic Europe Equity Income Fund (the "Fund") (NYSE: FDEU) has declared the Fund’s regularly scheduled monthly common share distribution in the amount of $0.07 per share payable on April 17, 2023, to shareholders of record as of April 4, 2023.
  • Under the Plan, the Fund intends to continue to pay a monthly distribution in the amount of $0.07 per share.
  • This distribution may consist of net investment income earned by the Fund, net short-term and long-term capital gains and/or tax deferred return of capital.
  • The Fund is a diversified, closed-end management investment company that seeks to provide a high level of current income.

LEO Pharma Presents Late-Breaking Positive Phase 3 Results of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (CHE) at AAD 2023

Retrieved on: 
Saturday, March 18, 2023
Managed Care, Pharmaceutical, Health, Clinical Trials, Janus, American Academy of Dermatology, American Academy, JAK, IGA, Leo Pharma, Patient, AAD, CHE, DELTA, Week, Safety, LEO, Pharmaceutical industry, Silviculture

The DELTA 1 trial randomized 487 adults with moderate-to-severe CHE to twice-daily delgocitinib cream 20 mg/g (n=325) or cream vehicle (n=162) for 16 weeks followed by a 36-week extension trial.

Key Points: 
  • The DELTA 1 trial randomized 487 adults with moderate-to-severe CHE to twice-daily delgocitinib cream 20 mg/g (n=325) or cream vehicle (n=162) for 16 weeks followed by a 36-week extension trial.
  • A significantly greater proportion of delgocitinib-treated patients, compared to cream vehicle, achieved this IGA-CHE improvement (19.7% vs. 9.9%; p=0.006).
  • A significantly greater proportion of delgocitinib-treated patients achieved a ≥75% improvement in Hand Eczema Severity Index (HECSI-75) compared to cream vehicle (49.2% vs. 23.5%; p
  • We are incredibly excited to share the positive results of this trial, which demonstrates the potential that delgocitinib cream has as a first-in-class innovative topical treatment.”

Janus International Group Reports Record Fourth Quarter and Full Year 2022 Results; Introduces Long Term Outlook for Sustained Organic Growth and Margin Expansion

Retrieved on: 
Thursday, March 16, 2023
Architecture, Commercial Building & Real Estate, Construction & Property, Other Manufacturing, Building Systems, Other Construction & Property, Manufacturing, Residential Building & Real Estate, ACT, CFO, Accounting, Fourth, Webcast, NYSE, Regulation S-K, Commercial, Regulation, Adjustment, EBITDA, International Marxist Group, GAAP, Steel, Growth, JBI, Management, Video game, Pharmaceutical industry, Real estate, Marketing, Janus

Net income was $32.7 million, or $0.22 per diluted share, compared to $10.3 million, or $0.07 per diluted share in the fourth quarter of 2021.

Key Points: 
  • Net income was $32.7 million, or $0.22 per diluted share, compared to $10.3 million, or $0.07 per diluted share in the fourth quarter of 2021.
  • Adjusted earnings per diluted share was $0.22, compared to $0.14 in the fourth quarter of 2021.
  • The year over year increase is attributable to the same items described in the Fourth Quarter 2022 Highlights above.
  • The year over year increase is attributable to the same items described in the Fourth Quarter 2022 Highlights above.

First Trust Dynamic Europe Equity Income Fund Issues Notice Regarding March 2023 Distribution

Retrieved on: 
Wednesday, March 15, 2023
Professional Services, Finance, Janus, Investment, US, City, REIT, FINRA, Vaccine, Net asset value, AIB (NI), NYSE, Economic development, Risk, European, FTP, Internal Revenue Code, Indian stock exchange, Notice, NAV, European Central Bank, FTA, Judgement, Social change, COVID-19, Loss, Fraud, Disease, Central bank, ERISA, Calendar, Infection, Janus Henderson, Fund, Terrorism, Uncertainty, Real estate investment trust, Clothing, Life insurance, Financial adviser, Bank, Security (finance), Euro, EU

The Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of your distribution may be a return of capital.

Key Points: 
  • The Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of your distribution may be a return of capital.
  • A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with "yield" or "income."
  • The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.
  • First Trust Advisors L.P. ("FTA") is a federally registered investment advisor and serves as the Fund's investment advisor.

ASLAN Pharmaceuticals to Host Virtual Research and Development Day on Novel DHODH Inhibitor Farudodstat for Alopecia Areata

Retrieved on: 
Wednesday, March 8, 2023
Janus, MD, SAN, Atopic dermatitis, AA, Hair loss, Skin, KOL, IP, Granuloma annulare, ASLN, Yale University, Scalp, JAK, Vitiligo, Yale School of Medicine, Patient, Associate, Autoimmune disease, Hair, DHODH, Immune privilege, Lichen planus, Alopecia areata, Sarcoidosis, Pharmaceutical industry, Dermatology

Farudodstat has been shown to inhibit IFN-γ secretion, reduce immune cell proliferation, and potentially protect hair follicles from IP collapse in a human AA disease model.

Key Points: 
  • Farudodstat has been shown to inhibit IFN-γ secretion, reduce immune cell proliferation, and potentially protect hair follicles from IP collapse in a human AA disease model.
  • ASLAN plans to initiate a proof-of-concept study of farudodstat in AA in the second quarter of 2023.
  • A replay of the event and presentation materials will be available on the Investor Relations section of ASLAN’s website .
  • He has pioneered the use of Janus kinase (JAK) inhibitors in dermatology, in particular for alopecia areata, vitiligo, atopic dermatitis, granuloma annulare, sarcoidosis, erosive lichen planus, and other disorders.

Ron Sachs Joins Givinga Board of Directors

Retrieved on: 
Tuesday, March 7, 2023
Data Management, Philanthropy, Technology, Other Technology, Other Philanthropy, Software, Networks, Janus, Sachs, Janus Capital Group, ROI, Financial adviser

Boston-based philanthropic technology company Givinga, Inc. has appointed Growth Capital Investor and Advisor Ron Sachs to their Board of Directors.

Key Points: 
  • Boston-based philanthropic technology company Givinga, Inc. has appointed Growth Capital Investor and Advisor Ron Sachs to their Board of Directors.
  • With an extensive investment management background, Sachs will bring insight and experience to the board as Givinga transitions into a critical growth stage.
  • “Ron has been an investor in Givinga for well over two years.
  • “I am excited to join Givinga’s Board to help the Givinga team continue to innovate and streamline corporate and individual philanthropy.

Janus Henderson Economists Win Harry M. Markowitz Award

Retrieved on: 
Monday, March 6, 2023
Asset Management, Professional Services, Finance, Janus, Knowledge, Nobel Prize, Janus Henderson, City, Scholes, Doctor of Philosophy, Investment management, NYSE, Black–Scholes model, Research, Carbon, ARD International Music Competition, Economics, Harry, ESG, Risk, ASX, Journal of Investment Management, University of California, San Diego, UC, Cryptocurrency

Myron holds the position of Chief Investment Strategist at Janus Henderson Investors.

Key Points: 
  • Myron holds the position of Chief Investment Strategist at Janus Henderson Investors.
  • Ashwin is the Head of Global Asset Allocation at Janus Henderson Investors.
  • All opinions and estimates in this information are subject to change without notice
    Issued by Janus Henderson Investors.
  • Janus Henderson Investors is the name under which investment products and services are provided by SEC registered investment advisers that are subsidiaries of Janus Henderson Group plc
    Janus Henderson, Knowledge Shared and Knowledge Labs are trademarks of Janus Henderson Group plc or one of its subsidiaries.

Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
Monday, March 6, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Cream, Shift, Janus, American Academy, Chronic, Journal, Dermatology, Conference call, Patient, Interest, Hidradenitis suppurativa, American Academy of Dermatology, AAD, Janus kinase inhibitor, Inflammation, JAK1, Use, Adolescence, Atopic dermatitis, Randomness, Post hoc analysis, Autoimmunity, Maintenance, JAAD, Conference, Abstract, HS, Safety, Cryptocurrency, Pharmaceutical industry, Communications satellite, Disease, Vitiligo, Incyte

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2023 American Academy of Dermatology (AAD) Annual Meeting, held March 17-21, 2023, in New Orleans.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2023 American Academy of Dermatology (AAD) Annual Meeting, held March 17-21, 2023, in New Orleans.
  • “The research being featured at this year’s AAD Annual Meeting highlights the potential of Incyte therapies to meet the needs of patients living with vitiligo and other serious skin conditions,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte.
  • Saturday, March 18, 9:30 a.m. CT)
    Efficacy and Safety of Povorcitinib in Vitiligo: Results from a Phase 2, Placebo-Controlled, Dose Ranging Study (Session: S042 – Late-Breaking Research: Session 2.
  • They will also be published online via the Journal of the American Academy of Dermatology (JAAD) supplement in Fall 2023.

Janus International Group to Report Fourth Quarter 2022 Results and Provide Long-Term Outlook on March 16, 2023

Retrieved on: 
Monday, March 6, 2023
Architecture, Commercial Building & Real Estate, Construction & Property, Other Manufacturing, Building Systems, REIT, Manufacturing, Residential Building & Real Estate, Janus, Conference, JBI, Webcast, NYSE, Domestic, International, International Marxist Group, Video game

A webcast and conference call will be held that same day at 10:00 a.m. Eastern time to review the Company’s fourth quarter and full year results, discuss its long-term strategic and financial outlook, and conduct a question-and-answer session.

Key Points: 
  • A webcast and conference call will be held that same day at 10:00 a.m. Eastern time to review the Company’s fourth quarter and full year results, discuss its long-term strategic and financial outlook, and conduct a question-and-answer session.
  • For those unable to access the webcast, the conference call will be accessible domestically or internationally, by dialing 1-877-407-0789 or 1-201-689-8562, respectively.
  • Upon dialing in, please request to join the Janus International Group Fourth Quarter 2022 Earnings Conference Call.
  • To access the replay of the call, dial 1-844-512-2921 (Domestic) and 1-412-317-6671 (International) with pass code 13735631.

Bicara Therapeutics Announces Oversubscribed $108 Million Series B Financing to Advance Clinical-Stage Pipeline of Dual-Action Biologics to Treat Cancer

Retrieved on: 
Monday, March 6, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Janus, Ketan, MBA, Capital, EGFR, Winklevoss Capital Management, Investigational New Drug, Head, Therapy, Patient, INVU (song), Cancer, Safety, Pharmaceutical industry

Bicara Therapeutics , a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable anti-tumor response, today announced that it completed an oversubscribed $108 million Series B financing to advance its lead program BCA101 and its pipeline of investigational candidates to treat solid tumor cancers.

Key Points: 
  • Bicara Therapeutics , a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable anti-tumor response, today announced that it completed an oversubscribed $108 million Series B financing to advance its lead program BCA101 and its pipeline of investigational candidates to treat solid tumor cancers.
  • New investors include Omega Funds, Bioqube Ventures, Acorn Bioventures and Janus Henderson Investors.
  • Additionally, the Company continues to advance Investigational New Drug-enabling studies for BCA356, a second precision tumor modulator program.
  • This investment is a strong fit for our fund as we seek to invest in early-stage companies that are developing transformational biologics that address diseases with high unmet needs.”